Skip to main content
. 2022 Jun 13;24:141. doi: 10.1186/s13075-022-02836-4

Table 2.

Comparison of outcomes according to the exposure to TNFis

Total (N = 450) TNFi exposed (N = 233) TNFi not exposed (N = 217) P value
Incident cardiovascular disease, n (%) 20 (4.44) 6 (2.6) 14 (6.5) 0.046
Duration of follow-up, years, median (IQR) 5.5 (2.9–9.4) 6.3 (3.4–10.2) 4.7 (2.8–8.2) 0.002
Time to events, years, median (IQR) 3.9 (1.8–7.2) 3.3 (2.0–8.4) 4.4 (1.7–7.0) > 0.999

TNFi tumor necrosis factor inhibitor, ESR erythrocyte sedimentation rate, CRP C-reactive protein